New combo therapy targets hard-to-treat lung cancer
Disease control
Completed
This early-phase study tested a new drug (ONO-7475) combined with the standard targeted therapy osimertinib in 78 people with advanced EGFR-mutated non-small cell lung cancer that cannot be treated with radiation. The main goals were to check safety and find the right dose. Resea…
Phase: PHASE1 • Sponsor: Ono Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Apr 26, 2026 19:38 UTC